Investment case
AstraZeneca PLC
AZN · 22 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 22 macro, policy, and market developments to AstraZeneca PLC since 2026-08-28. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for AZN yet, so no modelled value is shown. The AZN valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run AZN on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
Direct revenue potential from new drug combination approval, expanding market share in NSCLC.
· Moves peak sales estimates for tagrisso and orpathys, probability of success for pipeline assets, market share in nsclc
- Main threat
Ionis slides over 40% year-to-date following late-stage clinical setbacks
Partnered drug development. Pelacarsen is a co-development program with AstraZeneca. Setbacks directly impact potential future milestone payments and shared profits.
· Moves probability of success for pelacarsen, peak sales estimates for pelacarsen, future milestone payments from ions
- Open question
Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease
Potential indirect competitive pressure or market dynamics shift in kidney disease treatment. While not directly involved in these specific drugs, AZN has a significant presence in renal and rare disease markets.
· Moves market share for existing or pipeline kidney disease treatments, competitive landscape in renal disease
What changed, by assumption
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
- 2026-09-24HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026
- 2026-08-31HUTCHMED and AstraZeneca report positive Phase III SANOVO lung cancer trial data
- 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer
- 2026-08-31HUTCHMED and AstraZeneca Report Positive Phase III SANOVO Trial in China
- 2026-09-24Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress
- 2026-09-24HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMO
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-06 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-08-06 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-08-06 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer | Bullish | 3-12m | 0.60 |
| 2026-09-29 | AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer | Bullish | 3-12m | 0.80 |
| 2026-09-29 | AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer | Bullish | 3-12m | 0.70 |
| 2026-09-24 | Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress | Bullish | 3-12m | 0.60 |
| 2026-09-24 | Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial | Bearish | 3-12m | 0.30 |
| 2026-09-24 | HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMO | Bullish | 1-3m | 0.60 |
| 2026-09-24 | HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026 | Bullish | 1-3m | 0.75 |
| 2026-09-24 | Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease | watch | 3-12m | 0.30 |
| 2026-09-24 | HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMO | Bullish | 1-3m | 0.60 |
| 2026-09-24 | HUTCHMED to Present Phase III Savolitinib Lung Cancer Data at ESMO 2026 | Bullish | 1-3m | 0.60 |
| 2026-09-21 | Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and Eplontersen | Bearish | 3-12m | 0.20 |
| 2026-09-21 | Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets | watch | 3-12m | 0.30 |